NGS
Development and Testing of Reference Materials for NGS based Somatic Variant Detection and Fusion Detection in Myeloid Cancers
See how the development of these reference materials aid the development, optimization, and verification of NGS-based myeloid disease testing, providing laboratories greater assurance in their ability to correctly detect these genomic events in myeloid patient samples.
Cancer
Plasma Mutation Spectrum Matches Known Tumor Mutations in Active Cancer Patients
UNC evaluated a test system that preferentially amplifies fragmented DNA to reduce impact of ex vivo release of cellular DNA, and that capitalizes on “unique molecular identifiers” and variable amplicon lengths to improve assay performance.
ctDNA
Evaluation of Customizable Circulating Tumor DNA (ctDNA) Reference Materials with Multiple Assays
The utility of circulating cell-free DNA (ccfDNA) has led to the development of an ever-increasing number of ctDNA assays that also make use of fundamentally different analytic methods.
ctDNA
Application of the Highly Sensitive SiMSen-Seq Assay and Seraseq®-Designed Reference Materials to Minimal Residual Disease Detection
The reliable detection of minimal residual disease (MRD) becomes possible as ctDNA assays become more sensitive. Sensitive assays require matched reference materials.
NGS
Flexible Tools For The Development And Performance Verification Of Customized Target Enrichment Panels
Implementation of next generation sequencing for variant identification and discovery presents difficulties both in the selection of genomic loci for inclusion in a panel, as well as the ability
ctDNA
Multi-Laboratory Assessment of a New Reference Material for Quality Assurance of Circulating Tumor DNA Measurements
The accurate diagnosis and monitoring of cancer, using circulating tumor DNA, is a major challenge, given the low concentration and complexity of the target molecules.
ccfDNA
Donor-Derived Circulating Cell-Free DNA (ccfDNA) Reference Materials for Concordance Studies
The limited quantities of ccfDNA in plasma and the limited amount of ccfDNA that can therefore be obtained from a single donor can make it difficult to assess the sensitivities and specificities of
ctDNA
A Comprehensive, Targeted NGS Method That Rapidly And Accurately Detects Circulating Tumor DNA Variants At 0.1% Frequency In Plasma Samples
Mutation analysis of circulating tumor DNA (ctDNA) in blood-based liquid biopsies provides a minimally invasive approach to detect and monitor disease.
RNA Fusion
Use of Highly Multiplexed Reference Materials to Facilitate Validation of a Clinical NGS Tumor Fusion RNA Assay
NGS Tumor Fusion RNA Assay Next-generation sequencing (NGS) assays for detection of tumor RNA fusions must undergo rigorous validation before clinical implementation.
VariantFlex
Custom VariantFlex Technology Allows Rapid Design and Testing of Reference Materials for Tumor Genotyping Assays
Development and validation of tumor genotyping assays requires highly characterized reference materials for effective assessment of accuracy, precision,
CNVs
Development of Well Characterized Breast, Lung, and Brain Cancer Copy Number Variation Reference Materials
Copy number variation (CNV) can be a key driver of oncogenesis. Pathogenic CNVs are often associated with unfavorable prognosis and drug resistance.
NGS
Reliable Interpretation of NGS Data Using Well-Established, Highly-Multiplexed Reference Material
This video shows how Directed Genomics and New England Biolabs use highly multiplexed reference materials during optimization and validation to fine-tune assay performance.
ctDNA
An Efficient and Ultrasensitive Next-Generation Sequencing Solution for Profiling Circulating Tumor DNA
Next-generation sequencing (NGS) of liquid biopsies offers a minimally invasive alternative to solid tissue biopsies and a more holistic profile of intra- and inter-tumoral heterogeneity for therapy selection and disease monitoring.
RNA Fusion
Assessing Sensitivity of NGS RNA Fusion Assays Using a Multiplexed and Well-Characterized Linearity Panel
Many targeted NGS-based panels have been introduced to detect RNA fusions useful for prognosis and therapy selection in cancer.
ccfDNA
Circulating Cell Free DNA Isolated and Amplified from the Plasma of Pancreatic Cancer Patients as Reference Material for ctDNA Assays
The validation and evaluation of circulating tumor DNA (ctDNA) assays poses analytical challenges because the amount of circulating cell-free DNA (ccfDNA) that can be obtained
ctDNA
Patient-Like Circulating Tumor DNA Reference Materials for Evaluation of Next-Generation Sequencing Tests
Clinical oncologists are relying on analysis of circulating tumor DNA (ctDNA) across an increasing number of applications.
Zika
AccuSpan™ Zika Linearity Panel Spans the Dynamic Range of Assays and Allows Evaluation of Analytical Sensitivity
In response to the Zika virus outbreak, several PCR-based assays have been developed and approved under the Emergency Use Authorization (EUA).
NGS
Multiplexed Next-Generation Sequencing Reference Materials for Testing of Inherited Disorders
Next-generation sequencing (NGS) has rapidly advanced the genetic testing for inherited disorders.
ctDNA
A Commutable Circulating Tumor DNA (ctDNA) Reference Material
Commutability is an important aspect of reference materials and relates to how well the materials can mimic the natural analyte.
RNA Fusion
Digital PCR-Characterized, Highly Multiplexed, Oncology RNA Fusion Reference Materials: Performance on Multiple NGS Platforms
Genomic structural alterations are increasingly actionable for targeted therapeutics and personalized medicine.
NGS
Development of Highly Multiplexed Reference Materials for Inherited Cancer Testing
Next Generation sequencing (NGS) has improved the diagonistic yield of genetic testing, but has presented new challenges for test development, validation and quality control management.
Zika
Use of AccuPlex Recombinant Sindbis Virus Technology to Produce a Non-Infectious, Whole Process Zika Control
Our proprietary recombinant virus technology allows us to create safe, non-infectious, full-process controls for a range of infectious disease assays, including Zika and other emerging viruses.